Exploring the Factors Associated With the Discontinuation of Tofacitinib in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study

The RA patients who received tofacitinib in this study had a good response rate, and the average non-response rate was around 37% after 2 years of treatment. The main factor associated with an inadequate response to tofacitinib was prior bDMARD treatment. Prior TNFi treatment was the strongest factor associated with a non-response to tofacitinib. Patients with a non-response to tofacitinib may consider bDMARDs with other mechanisms if previous treatment with TNFis was unsuccessful.